Boubacar Coulibaly

Boubacar Coulibaly

Auto-generated profile, based on publicly available information

Boubacar Coulibaly

Centre de Recherche en Santé de Nouna, Burkina Faso

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2008 in Malaria Journal
Verified
Journal Article
Open access
PDF file
MTMaike Tipke
Maike Tipke
SDSalou Diallo
Salou Diallo
BCBoubacar Coulibaly
Boubacar Coulibaly
DSDominic Störzinger
Dominic Störzinger
THTorsten Hoppe-Tichy
Torsten Hoppe-Tichy
OMOlaf Müller
Olaf Müller
There is concern about an increasing infiltration of markets by substandard and fake medications against life-threatening diseases in developing countries. This is particularly worrying with regard to the increasing resistance development of Plasmodium falciparum against affordable anti-malarial medications, which has led to a change to more expensive drugs in most endemic countries.

7 February 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
TDThuy Doan
Thuy Doan
ZLZijun Liu
Zijun Liu
ASAli Sié
Ali Sié
CDClarisse Dah
Clarisse Dah
MBMamadou Bountogo
Mamadou Bountogo
TLTom Lietman
Tom Lietman
: Mass antibiotic distribution to preschool children resulted in alterations of the gut microbiome months after distribution. This individually randomized, placebo-controlled trial evaluated changes in the gut microbiome and resistome in children aged 8 days to 59 months after one dose of oral azithromycin in Burkina Faso. A total of 450 children were randomized in a 1:1 ratio to either placebo or azithromycin. Rectal samples were collected at baseline, 2 weeks, and 6 months after randomization and subjected to DNA deep sequencing. Gut microbiome diversity and normalized antimicrobial resistance determinants for different antibiotic classes were evaluated. Azithromycin decreased gut bacterial diversity (Shannon P < 0.0001; inverse Simpson P < 0.001) 2 weeks after treatment relative to placebo. Concurrently, the normalized abundance of macrolide resistance genetic determinants was 243-fold higher (95% CI: 76-fold to 776-fold, P < 0.0001). These alterations did not persist at 6 months, suggesting that disruptions were transient. Furthermore, we were unable to detect resistance changes in other antibiotic classes, indicating that co-resistance with a single course of azithromycin when treated at the individual level was unlikely.

2 September 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
AHArmin Hinterwirth
Armin Hinterwirth
ASAli Sié
Ali Sié
BCBoubacar Coulibaly
Boubacar Coulibaly
LOLucienne Ouermi
Lucienne Ouermi
CDClarisse Dah
Clarisse Dah
COCatherine E. Oldenburg
Catherine E. Oldenburg
Campylobacter has emerged as a potential important cause of childhood morbidity in sub-Saharan Africa. Biannual mass azithromycin distribution has previously been shown to reduce all-cause child mortality in sub-Saharan Africa. We conducted a randomized controlled trial in Burkina Faso in which children were randomized in a 1:1 fashion to a 5-day course of azithromycin or placebo to investigate the effect of oral antibiotics on the gut microbiome. We evaluated the changes in the gut microbiome of preschool children treated with azithromycin using metagenomic DNA sequencing. We found that three Campylobacter species were reduced with azithromycin treatment compared with placebo. These results were consistent with other studies that have shown decreases in Campylobacter species after azithromycin treatment, generating the hypothesis that a decrease in Campylobacter may contribute to observations of reduction in mortality following azithromycin distribution.

30 December 2015 in Malaria Journal
Verified
Journal Article
Open access
PDF file
Guangyu LuGuangyu Lu
Guangyu Lu
CTCorneille Traoré
Corneille Traoré
PMPeter Meissner
Peter Meissner
BKBocar Kouyaté
Bocar Kouyaté
GKGisela Kynast-Wolf
Gisela Kynast-Wolf
OMOlaf Müller
Olaf Müller
Insecticide-treated bed nets (ITNs) are now the main tool for malaria prevention in endemic areas. Synthetic pyrethroids are the only group of insecticides recommended by the World Health Organization for the use on ITNs. There are only few studies which have specifically investigated potential adverse effects of frequent exposure to ITNs in the vulnerable group of young infants and their mothers. This study was nested into a large randomized controlled ITN effectiveness trial. Ninety newborns and their mothers were selected from the study population for participation. Together with their mothers they were protected with ITNs from birth (group A, n = 45) or from age 6 months (group B, n = 45) and followed up for 18 weeks (daily visits in the first 4 weeks, weekly visits thereafter). Potential side effects related to synthetic pyrethroids (deltamethrin) exposure were systematically investigated by trained field staff. The frequency and duration of respective symptoms was compared between the two study groups. A total of 180 participants (90 mothers and 90 infants) were followed up over the study period without any loss to follow up. There were no significant differences in the frequency and duration of side effects between the two study groups, except that the frequency of headache was significantly higher in group A compared to group B mothers (p = 0.01). The study provides further evidence for ITNs being sufficiently safe in children and even in newborns. The association with headache in mothers could be explained by them handling the ITNs more intensely or it could be a chance finding.

23 May 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
BCBoubacar Coulibaly
Boubacar Coulibaly
DKDramane Kiemde
Dramane Kiemde
GZGuillaume Zonou
Guillaume Zonou
ASAli Sié
Ali Sié
CDClarisse Dah
Clarisse Dah
COCatherine E. ScD Oldenburg
Catherine E. ScD Oldenburg
We evaluated antibiotic resistance selection in Streptococcus pneumoniae isolates from children participating in an individually randomized trial of single-dose azithromycin versus placebo. After 14 days, the prevalence of resistance to erythromycin, oxacillin, and clindamycin was elevated in the azithromycin versus placebo group. There was no difference at 6 months.

21 December 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
ASAli Sié
Ali Sié
CDClarisse Dah
Clarisse Dah
MBMamadou Bountogo
Mamadou Bountogo
MOMamadou Ouattara
Mamadou Ouattara
ENEric Ipyn Nébié
Eric Ipyn Nébié
FGfor the GAMIN Study Group
for the GAMIN Study Group
Biannual mass azithromycin distribution reduces all-cause child mortality in some settings in sub-Saharan Africa; however, adverse events and short-term infectious outcomes following treatment have not been well characterized. Children aged 0–59 months were recruited in Nouna Town, Burkina Faso, and randomized 1:1 to a single directly observed oral 20 mg/kg dose of azithromycin or placebo. At 14 days after treatment, caregivers were interviewed about adverse event symptoms their child experienced since treatment and if they had sought health care for their child. All children had tympanic temperature measured at the 14-day visit. We compared adverse events and clinic visits using logistic regression models between azithromycin- and placebo-controlled children. Of 450 children enrolled, 230 were randomized to azithromycin and 220 to placebo. On average, children were aged 28 months, and 50.9% were female. Caregivers of 20% of children reported that their child experienced at least one adverse event, with no significant difference between study arms (19.9% azithromycin; 20.0% placebo, logistic regression P = 0.96). Vomiting was more often reported by caregivers of azithromycin-treated children than by those of placebo-treated children (7.2% azithromycin, 1.9% placebo, logistic regression P = 0.01). There were no significant differences in other adverse events or clinic visits. Adverse events following a single oral dose of azithromycin in preschool children were rare and mild. Azithromycin administration appears safe in this population.